[Research on tissue regeneration and engineered scaffold materials in prevention and treatment of lymphedema]
Yuan S., Deng C.
Narrative Review, published in Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41839568
- PMCID
- PMC12991884
- DOI
- 10.7507/1002-1892.202509027
Abstract (original English)
Objective To summarize the research in tissue regeneration and engineered scaffold materials for the prevention and treatment of lymphedema. Methods The recent domestic and international literature about lymphangiogenesis-related factors, stem cells, and tissue engineered scaffold materials for the prevention and treatment of lymphedema was extensively reviewed and summarized, and the progress of tissue engineered scaffold materials in prevention and treatment of lymphedema was emphatically introduced. Results Lymphangiogenesis-related factors, stem cells, and tissue engineered scaffold materials utilize two main strategies to prevent and treat lymphedema: promoting lymphatic network regeneration in vivo and constructing functional lymphatic tissues for transplantation in vitro . Conclusion Tissue regeneration and engineered scaffold materials provide new approaches for the prevention and treatment of lymphedema. Although innovative developments have been made, most are still at the basic research stage, and clinical translation remains a challenge.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.